Literature DB >> 6611553

Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: characterization and localization of receptor binding sites in rat and human brain.

J A Javitch, G R Uhl, S H Snyder.   

Abstract

N-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces neuropathologic and clinical abnormalities in humans and animals that closely resemble idiopathic Parkinson disease. [3H]MPTP binds with high affinity (Kd = 28 X 10(-9) M) to brain membranes. The chemical specificity of the binding sites corresponds to structure-activity requirements for neurotoxicity. Autoradiographic studies in human brain show very high receptor densities in the caudate, substantia nigra, and locus coeruleus, which may explain the neurotoxic and neurochemical sequelae of MPTP administration. In contrast to the human, rat substantia nigra and caudate display only moderate receptor concentrations. This species difference may explain the difficulty in producing selective nigrostriatal degeneration in rats. Sites densely labeled in rat brain include the locus coeruleus, interpeduncular nucleus, arcuate and periventricular hypothalamic nuclei, and the subfornical organ.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6611553      PMCID: PMC345637          DOI: 10.1073/pnas.81.14.4591

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  15 in total

Review 1.  Developments in the pharmacology and therapeutics of parkinsonism.

Authors:  D B Calne
Journal:  Ann Neurol       Date:  1977-02       Impact factor: 10.422

2.  The brain-stem lesions in Parkinsonism.

Authors:  J G GREENFIELD; F D BOSANQUET
Journal:  J Neurol Neurosurg Psychiatry       Date:  1953-11       Impact factor: 10.154

3.  A practical computer-based approach to the analysis of radioligand binding experiments.

Authors:  G A McPherson
Journal:  Comput Programs Biomed       Date:  1983 Aug-Oct

4.  Melanin affinity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine, an inducer of chronic parkinsonism in humans.

Authors:  A Lydén; U Bondesson; B S Larsson; N G Lindquist
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1983-11

5.  Quantitative receptor autoradiography using [3H]ultrofilm: application to multiple benzodiazepine receptors.

Authors:  J R Unnerstall; D L Niehoff; M J Kuhar; J M Palacios
Journal:  J Neurosci Methods       Date:  1982-07       Impact factor: 2.390

6.  Autoradiographic visualization of angiotensin-converting enzyme in rat brain with [3H]captopril: localization to a striatonigral pathway.

Authors:  S M Strittmatter; M M Lo; J A Javitch; S H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  1984-03       Impact factor: 11.205

7.  Chronic Parkinsonism secondary to intravenous injection of meperidine analogues.

Authors:  G C Davis; A C Williams; S P Markey; M H Ebert; E D Caine; C M Reichert; I J Kopin
Journal:  Psychiatry Res       Date:  1979-12       Impact factor: 3.222

8.  Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey.

Authors:  J W Langston; L S Forno; C S Rebert; I Irwin
Journal:  Brain Res       Date:  1984-02-06       Impact factor: 3.252

9.  Neurotoxicity of the meperidine analogue N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on brain catecholamine neurons in the mouse.

Authors:  H Hallman; L Olson; G Jonsson
Journal:  Eur J Pharmacol       Date:  1984-01-13       Impact factor: 4.432

10.  Basal forebrain neurons in the dementia of Parkinson disease.

Authors:  P J Whitehouse; J C Hedreen; C L White; D L Price
Journal:  Ann Neurol       Date:  1983-03       Impact factor: 10.422

View more
  14 in total

1.  Platelet monoamine oxidase B activity in parkinsonian patients.

Authors:  U Bonuccelli; P Piccini; P Del Dotto; G M Pacifici; G U Corsini; A Muratorio
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-10       Impact factor: 10.154

2.  Brain stem catecholamines circuitry: activation by alcohol and role in the hypothalamic-pituitary-adrenal response to this drug.

Authors:  S Lee; Z Craddock; C Rivier
Journal:  J Neuroendocrinol       Date:  2011-06       Impact factor: 3.627

Review 3.  The hypothalamus in MPTP-induced parkinsonism.

Authors:  R Sandyk; R P Iacono; S R Kay
Journal:  Ital J Neurol Sci       Date:  1990-08

4.  The interaction of 1-alkyl-4,4-diphenylpiperidines with the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine receptor binding site.

Authors:  H Russ; U Pindur; H Przuntek
Journal:  J Neural Transm       Date:  1986       Impact factor: 3.575

5.  Regional dopamine transporter gene expression in the substantia nigra from control and Parkinson's disease brains.

Authors:  T J Counihan; J B Penney
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-08       Impact factor: 10.154

6.  p10, the N-terminal domain of p35, protects against CDK5/p25-induced neurotoxicity.

Authors:  Lingyan Zhang; Wen Liu; Karen K Szumlinski; John Lew
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-14       Impact factor: 11.205

7.  Cerebral bioimaging of Cu, Fe, Zn, and Mn in the MPTP mouse model of Parkinson's disease using laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS).

Authors:  Andreas Matusch; Candan Depboylu; Christoph Palm; Bei Wu; Günter U Höglinger; Martin K-H Schäfer; J Sabine Becker
Journal:  J Am Soc Mass Spectrom       Date:  2009-10-06       Impact factor: 3.109

8.  Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity.

Authors:  J A Javitch; R J D'Amato; S M Strittmatter; S H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  1985-04       Impact factor: 11.205

9.  Quantitative autoradiography of brain binding sites for the vesicular acetylcholine transport blocker 2-(4-phenylpiperidino)cyclohexanol (AH5183).

Authors:  M R Marien; S M Parsons; C A Altar
Journal:  Proc Natl Acad Sci U S A       Date:  1987-02       Impact factor: 11.205

10.  Decreased vesicular monoamine transporter 2 (VMAT2) and dopamine transporter (DAT) function in knockout mice affects aging of dopaminergic systems.

Authors:  F S Hall; K Itokawa; A Schmitt; R Moessner; I Sora; K P Lesch; G R Uhl
Journal:  Neuropharmacology       Date:  2013-08-24       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.